Your browser doesn't support javascript.
loading
CD36 as a double-edged sword in cancer.
Jiang, Muwei; Karsenberg, Renske; Bianchi, Frans; van den Bogaart, Geert.
Afiliación
  • Jiang M; Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Nijenborgh 7, Groningen, the Netherlands.
  • Karsenberg R; Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Nijenborgh 7, Groningen, the Netherlands.
  • Bianchi F; Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Nijenborgh 7, Groningen, the Netherlands.
  • van den Bogaart G; Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Nijenborgh 7, Groningen, the Netherlands. Electronic address: g.van.den.bogaart@rug.nl.
Immunol Lett ; 265: 7-15, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38122906
ABSTRACT
The membrane protein CD36 is a lipid transporter, scavenger receptor, and receptor for the antiangiogenic protein thrombospondin 1 (TSP1). CD36 is expressed by cancer cells and by many associated cells including various cancer-infiltrating immune cell types. Thereby, CD36 plays critical roles in cancer, and it has been reported to affect cancer growth, metastasis, angiogenesis, and drug resistance. However, these roles are partly contradictory, as CD36 has been both reported to promote and inhibit cancer progression. Moreover, the mechanisms are also partly contradictory, because CD36 has been shown to exert opposite cellular effects such as cell division, senescence and cell death. This review provides an overview of the diverse effects of CD36 on tumor progression, aiming to shed light on its diverse pro- and anti-cancer roles, and the implications for therapeutic targeting.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Antígenos CD36 / Neoplasias Límite: Humans Idioma: En Revista: Immunol Lett Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Antígenos CD36 / Neoplasias Límite: Humans Idioma: En Revista: Immunol Lett Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos